| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2023-12-15 |
| タイトル |
|
|
タイトル |
Implementation of monoclonal antibody therapy and new rehabilitation strategies for Alzheimer disease |
|
言語 |
en |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Alzheimer disease |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
immunotherapy |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
disease-modifying therapy |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
aducanumab |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
lecanemab |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
donanemab |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
rehabilitation |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_dcae04bc |
|
資源タイプ |
review article |
| ID登録 |
|
|
ID登録 |
10.69202/0002000010 |
|
ID登録タイプ |
JaLC |
| 内容種別 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Review Article |
| 著者 |
Masatoshi TAKEDA
Misa NAKAMURA
Hirotoshi UTSUNOMIYA
Tatsunori MURAKAMI
Junya SAEKI
Takanari KUBO
Yuya NAKAGOSHI
Nobuo OSHIMA
Keiko SAKAI
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
In June 2021, the United States Food and Drug Administration granted accelerated approval for aducanumab, the first monoclonal antibody drug to be used in clinical settings in the United States. Meanwhile, it has not received approval in Europe or in Japan owing to significant reduction of amyloid beta without evidence of slowing down the progression of cognitive decline of patients with early Alzheimer disease. In January 2023, outine approval was granted in the United States for a second antibody, lecanemab, which had sufficient evidence of clinical effect and significant deprivation of amyloid beta in the phase 3 trials. Lecanemab was pproved by the Japanese regulatory authorities in Japan in September 2023 after Eisai filed for approval in January. A framework for treatment of Alzheimer disease with antibody therapeutics is required. Although lecanemab has emonstrated efficacy, side effects including amyloid-related imaging abnormality have also been confirmed. Based on the results of clinical trials, there is ongoing discussion of the system for its use in clinical settings. ecanemab is expected to have disease-modifying effects and may inhibit the rate of cognitive decline in the early stage of Alzheimer disease, thereby prolonging the duration of mild stage period. This is also the period hen the rehabilitation is most effective, making psychosocial interventions more important than ever. Rehabilitation techniques need to be developed for patients with early Alzheimer disease receiving disease-modifying therapy. Although disease-modifying drugs inhibit the progression of symptoms in the early stages for a certain period of time, once the threshold is exceeded, cognitive function may decline more rapidly than in non-drug-treated individuals. From this perspective, the effects of disease-modifying therapy are analogous to the effect of high cognitive reserve. These considerations should be taken into account to enhance the clinical utility of rehabilitation for patients under disease-modifying therapy for Alzheimer disease. |
|
言語 |
en |
| 書誌情報 |
en : COGNITION & REHABILITATION
巻 4,
号 1,
p. 59-71,
ページ数 13,
発行日 2023-11-30
|
| 出版者 |
|
|
出版者 |
Osaka Kawasaki Rehabilitation University |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
2436-1097 |
p59-71_Masatoshi TAKEDA.pdf (975 KB)
